Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revusiran in TTR-mediated familial amyloidotic polyneuropathy after liver transplant
2015-002603-29Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2015
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of revusiran in familial amyloid polyneuropathy (FAP) and hereditary transthyretin amyloidosis (hATTR), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Percent reduction in serum TTR level at 6 months. Started Jul 2015; status: completed.
02
Drugs
revusiran
03
Conditions
familial amyloid polyneuropathy (FAP)hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on 2015-002603-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002603-29.